Get started
Author

Limin Shang

Observed name: L. Shang
ORCID: 0009-0004-1793-9871
Observed ORCID: 0009-0004-1793-9871
OpenAlex ID: A5020797592
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
2023 · Anja Seckinger, Sara Majocchi, et al. · Journal of Hematology & Oncology · 24
PDF
NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2025 · Sara Majocchi, Pauline Lloveras, et al. · Cancer Immunology Research · 12
PDF
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies
2025 · Julien Montorfani, Eric Hatterer, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
752P Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer
2022 · A. Seckinger, S. Majocchi, et al. · Annals of Oncology · 2
PDF
Abstract 2951: NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade
2023 · Xavier Chauchet, Sebastien Calloud, et al. · Cancer Research · 1
853 Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer
2022 · Anja Seckinger, Vanessa Buatois, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
TLR4 Activates the B-Catenin Pathway to Cause Intestinal Neoplasia
2012 · Rebeca Santaolalla, Jose Ruiz, et al. · Inflammatory Bowel Diseases · 1
A Reciprocally Masked Anti-CD47/IL2 Fusion Protein Promotes Antitumor Immunity and Limits Systemic Toxicity
2026 · Elise Léchine, Laura Cons, et al. · Cancer Immunology Research
PDF
Combination of bispecific antibodies enable targeted TNFRSF agonism and effective antitumor activity
2026 · Lucie Diby, Pauline Malinge, et al. · Molecular Therapy
Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S14 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S17 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S12 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S16 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S10 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Works count: 67
Citation count: 44
H-index: 3
I10-index: 2
Year
Topic
Type